298 related articles for article (PubMed ID: 34778801)
21. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
[TBL] [Abstract][Full Text] [Related]
22. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
25. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
[TBL] [Abstract][Full Text] [Related]
26. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Hatsumi N; Miyawaki S; Yamauchi T; Takeshita A; Komatsu N; Usui N; Arai Y; Ishida F; Morii T; Kano Y; Ogura M; Machida S; Nishii K; Honda S; Ohnishi K; Naoe T;
Int J Hematol; 2019 Apr; 109(4):418-425. PubMed ID: 30725360
[TBL] [Abstract][Full Text] [Related]
28. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
29. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
30. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
31. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
32. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
Tang W; Fan X; Wang L; Hu J
Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
[TBL] [Abstract][Full Text] [Related]
33. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M; Gui G; Dillon LW; Lindblad KE; Thompson J; Valdez J; Kim DY; Ghannam JY; Oetjen KA; Destefano CB; Smith DM; Tekleab H; Li Y; Dagur P; Hughes T; Marté JL; Del Rivero J; Klubo-Gwiezdzinksa J; Gulley JL; Calvo KR; Lai C; Hourigan CS
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017151
[TBL] [Abstract][Full Text] [Related]
36. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
[TBL] [Abstract][Full Text] [Related]
38. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
39. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
[TBL] [Abstract][Full Text] [Related]
40. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; Boluda B; Martínez P; Bergua J; Rodríguez-Veiga R; Esteve J; Vives S; Serrano J; Vidriales B; Salamero O; Cordón L; Sempere A; Jiménez-Ubieto A; Prieto-Delgado J; Díaz-Beyá M; Garrido A; Benavente C; Pérez-Simón JA; Moscardó F; Sanz MA; Montesinos P;
Ann Hematol; 2018 May; 97(5):763-772. PubMed ID: 29392425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
